11/18/2024
5:16 AM | Pontifax Management III G.P. Ltd. (0001726335) (Filed by)
UroGen Pharma (Subject)
| Form SC 13D/A | |
11/14/2024
6:46 PM | Point72 Asset Management, L.P. (Filed by)
UroGen Pharma (Subject)
| Form SC 13G/A | |
11/14/2024
4:46 PM | RA CAPITAL MANAGEMENT, L.P. (Filed by)
UroGen Pharma (Subject)
| Form SC 13G/A | |
11/14/2024
11:04 AM | MENORA MIVTACHIM HOLDINGS LTD. (Filed by)
UroGen Pharma (Subject)
| Form SC 13G/A | |
11/14/2024
7:37 AM | COWEN AND COMPANY, LLC (Filed by)
UroGen Pharma (Subject)
| Form SC 13G/A | |
11/14/2024
5:44 AM | RTW INVESTMENTS, LP (Filed by)
UroGen Pharma (Subject)
| Form SC 13G/A | |
11/12/2024
8:30 AM | Adage Capital Management, L.P. (Filed by)
UroGen Pharma (Subject)
| Form SC 13G | |
|
11/08/2024
1:17 PM | BlackRock, Inc. (Filed by)
UroGen Pharma (Subject)
| Form SC 13G | |
11/06/2024
12:50 PM | MORGAN STANLEY (Filed by)
UroGen Pharma (Subject)
| Form SC 13G | |
11/06/2024
7:01 AM | UroGen Pharma (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
11/06/2024
7:04 AM | UroGen Pharma (Filer)
| Form 10-Q
General form for quarterly reports under Section 13 or 15(d) | |
10/24/2024
1:02 PM | BlackRock, Inc. (Filed by)
UroGen Pharma (Subject)
| Form SC 13G | |
10/09/2024
3:21 PM | Degnan Chris (Reporting)
UroGen Pharma (Issuer)
| Form 3
Initial statement of beneficial ownership of securities | |
10/09/2024
3:22 PM | Degnan Chris (Reporting)
UroGen Pharma (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
10/09/2024
7:18 AM | UroGen Pharma (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
09/24/2024
3:15 PM | UroGen Pharma (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
09/12/2024
12:51 PM | Smith Jason Drew (Reporting)
UroGen Pharma (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
09/12/2024
12:54 PM | Schoenberg Mark (Reporting)
UroGen Pharma (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
09/12/2024
12:50 PM | Kim Dong (Reporting)
UroGen Pharma (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
09/10/2024
6:16 AM | Schoenberg Mark (Reporting)
UroGen Pharma (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
08/15/2024
7:00 AM | UroGen Pharma (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
08/13/2024
7:01 AM | UroGen Pharma (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
08/13/2024
7:05 AM | UroGen Pharma (Filer)
| Form 10-Q
General form for quarterly reports under Section 13 or 15(d) | |
08/08/2024
3:30 PM | UroGen Pharma (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
08/08/2024
8:06 AM | BUTITTA CYNTHIA M (Reporting)
UroGen Pharma (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
08/08/2024
8:07 AM | UroGen Pharma (Issuer)
WEN LEANA (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
08/08/2024
8:08 AM | Robinson James A. Jr. (Reporting)
UroGen Pharma (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
08/08/2024
8:09 AM | Holden Stuart (Reporting)
UroGen Pharma (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
08/08/2024
8:10 AM | UroGen Pharma (Issuer)
Wildman Daniel George (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
08/08/2024
8:11 AM | Cohen Fred E (Reporting)
UroGen Pharma (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
08/08/2024
8:11 AM | Belldegrun Arie (Reporting)
UroGen Pharma (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
07/09/2024
4:30 PM | UroGen Pharma (Filer)
| Form ARS | |
06/24/2024
4:25 PM | COWEN AND COMPANY, LLC (Filed by)
UroGen Pharma (Subject)
| Form SC 13G | |
06/24/2024
3:51 PM | Point72 Asset Management, L.P. (Filed by)
UroGen Pharma (Subject)
| Form SC 13G | |
06/18/2024
4:07 PM | UroGen Pharma (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
06/13/2024
9:51 AM | UroGen Pharma (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
06/11/2024
12:15 PM | Schoenberg Mark (Reporting)
UroGen Pharma (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/11/2024
5:16 AM | Schoenberg Mark (Reporting)
UroGen Pharma (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
05/13/2024
7:01 AM | UroGen Pharma (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
05/13/2024
7:05 AM | UroGen Pharma (Filer)
| Form 10-Q
General form for quarterly reports under Section 13 or 15(d) | |
05/08/2024
1:22 PM | BlackRock Inc. (Filed by)
UroGen Pharma (Subject)
| Form SC 13G/A | |
New Year, New Opportunity! 2 AI Stocks Under $10 Ready to Soar (Ad) As we step into 2025, artificial intelligence (AI) stocks continue to dominate headlines, and now is the perfect moment to position yourself for the coming year’s potential.
Our latest research has uncovered two must-buy AI stocks currently trading under $10/share – an affordable entry with promising growth potential. These stocks are flying under the radar, but it’s only a matter of time before they gain mainstream attention. 👉 Click here to access your FREE report now! |
04/29/2024
7:18 AM | UroGen Pharma (Filer)
| Form 10-K/A | |
03/20/2024
3:38 PM | Schoenberg Mark (Reporting)
UroGen Pharma (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
03/18/2024
12:48 PM | Schoenberg Mark (Reporting)
UroGen Pharma (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
03/14/2024
7:16 AM | UroGen Pharma (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
03/14/2024
7:17 AM | UroGen Pharma (Filer)
| Form 10-K
Annual report pursuant to Section 13 or 15(d) | |
03/04/2024
6:00 AM | UroGen Pharma (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
03/01/2024
6:00 AM | UroGen Pharma (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
02/22/2024
8:23 AM | Arkin Moshe (Filed by)
UroGen Pharma (Subject)
| Form SC 13D/A | |
02/14/2024
6:07 AM | RTW INVESTMENTS, LP (Filed by)
UroGen Pharma (Subject)
| Form SC 13G | |
02/12/2024
4:47 PM | Kim Dong (Reporting)
UroGen Pharma (Issuer)
| Form 4/A | |
02/12/2024
4:43 PM | Kim Dong (Reporting)
UroGen Pharma (Issuer)
| Form 4/A | |
02/07/2024
3:15 PM | UroGen Pharma (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
02/05/2024
8:15 PM | Schoenberg Mark (Reporting)
UroGen Pharma (Issuer)
| Form 4/A | |
02/05/2024
8:16 PM | Smith Jason Drew (Reporting)
UroGen Pharma (Issuer)
| Form 4/A | |
02/02/2024
6:04 PM | Barrett Elizabeth A. (Reporting)
UroGen Pharma (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/02/2024
6:05 PM | Kim Dong (Reporting)
UroGen Pharma (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/02/2024
6:07 PM | Schoenberg Mark (Reporting)
UroGen Pharma (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/02/2024
6:12 PM | Smith Jason Drew (Reporting)
UroGen Pharma (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/02/2024
1:18 PM | BlackRock Inc. (Filed by)
UroGen Pharma (Subject)
| Form SC 13G | |
02/01/2024
9:13 AM | Schoenberg Mark (Reporting)
UroGen Pharma (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
02/01/2024
8:53 AM | Smith Jason Drew (Reporting)
UroGen Pharma (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
01/17/2024
3:16 PM | UroGen Pharma (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
01/02/2024
7:04 AM | UroGen Pharma (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
12/29/2023
3:30 PM | RA CAPITAL MANAGEMENT, L.P. (Filed by)
UroGen Pharma (Subject)
| Form SC 13G | |
Free URGN Stock Alerts